Dostarlimab effective in rectal cancer subset

PD-1 blockade with adjuvant dostarlimab in mismatch repair–deficient, locally advanced rectal cancer shows signs of high efficacy, researchers reported on June 5, 2022 in the NEJM/ New England Journal of Medicine. As background, the authors noted, “Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal […]